mail Whup! Whup!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Get Well Sooon!.
Health & Medicine News.
http://www.sciencedaily.com/news/health_medicine/
Good Luck Diva!!
Garyst. I have Bot 4 times this go around.
Lost 60% or so the previous round. I would have to go look.
Averaged now at $0.000125
Lotsa shares for sure.
I like the prospects on AFPW. Potential is INTact.
I will say that with my last overweight triple 000
ticker DTSL I got killed.
But I am alive.
tommyboyboy. I am now overweight AFPW.
Whoa - I will take that 52 week high CJAKE1.
Health & Medicine News
http://www.sciencedaily.com/news/health_medicine/
Influenza Study: Meet Virus' New Enemy
Scientists Make Older Adults Less Forgetful in Memory Tests
Protein 'Passport' Helps Nanoparticles Get Past Immune System
Modeling Alzheimer's Disease Using iPSCs
Discovery of New Antivirals That Block the Progression of the Flu Virus
SHERBROOKE, QC, Feb. 22, 2013 /CNW Telbec/ - Dr. Martin Richter (pharmacology), investigator with the Centre de recherche clinique Étienne-Le Bel (CRCELB) at the Centre hospitalier universitaire de Sherbrooke (CHUS) and professor in the Faculty of Medicine and Health Sciences of the Université de Sherbrooke (UdeS), and his collaborators have identified a new function of the enzyme matriptase, present in the human respiratory system, that can activate a viral protein involved in infections caused by the H1N1 influenza (or flu) virus. Using this observation as a starting point, these researchers have discovered a new antiviral that targets the host rather than viruses, which could prevent viruses from acquiring drug resistance. Martin Richter's research findings provide a response to a critical need for new antivirals to treat the flu, which, even today, annually causes between 250,000 and 500,000 deaths across the world, especially among young children and the elderly.
Martin Richter and his coworkers at CRCELB and the Institut de pharmacologie de Sherbrooke (pharmacology institute), namely medical chemist Éric Marsault and biochemist/pharmacologist Richard Leduc, have developed molecules capable of blocking this enzyme's activity, which impairs the virus's propagation. The research team has filed an international patent application for a new class of influenza antivirals targeting matriptase and recently published its research findings in the renowned Journal of Virology.
Martin Richter's results demonstrate that biotechnology tools referred to as interfering RNA can be used to suppress matriptase expression in human bronchial epithelial cells. These cells cover the body's respiratory tract and are the main target of the flu virus. The team of researchers was therefore able to demonstrate that the enzyme's absence significantly blocked replication of the H1N1 virus. Without this enzyme present, these respiratory cells offer greater resistance to the flu virus. The researchers took their work a step further by using their novel inhibitor to suppress the enzyme's action. Indeed, they demonstrated that the inhibitor was highly effective in blocking replication of the H1N1 virus, which caused the 2009 pandemic.
The flu virus needs a key to enter a cell in order to spread within the respiratory system. This key, found on the virus's surface, is a protein referred to as hemagglutinin. In order for the key to work, it must be keyed properly so that the virus can enter the cell and replicate. The virus's genetic code doesn't provide the tools needed to shape the key, so the virus must use the host to do so. The virus therefore uses the host's enzymes to ensure its own replication. The enzymes act like a master locksmith that can key the virus's hemagglutinin and activate the entrance key. This lets the virus take control of the cell and allows its free replication, allowing the disease to propagate in the respiratory system.
As things stand, there are only two types of antivirals approved for treating the influenza virus (flu virus), including Tamiflu and Relenza, yet multiple strains of the flu virus are increasingly resistant to antivirals. Nearly all H3N2 strains are resistant to one of the two types of antivirals, so these medications are no longer recommended for treating influenza. In addition, several strains of H1N1 — all of which were circulating during the 2007-2008 flu season, were resistant to Tamiflu. Most strains derived from H1N1 virus — derived from the 2009 pandemic and still circulating today — remain susceptible but many cases of resistance have been detected.
As a result, Martin Richter's research opens the way to the development of new antivirals based on patent-pending technology. The Société de commercialisation et de valorisation de l'Université de Sherbrooke (SOCPRA) holds the intellectual-property rights to the results of this research, which is available for marketing partnerships.
Centre de recherche clinique Étienne-Le Bel, CHUS ::: www.crc.chus.qc.ca
Positioned at the cutting-edge of today's major health issues, the Centre de Recherche Clinique Étienne-Le Bel (CRCELB) of the Centre hospitalier universitaire de Sherbrooke (CHUS) stands out for its integrated approach in which fundamental, clinical, epidemiological, and evaluative research coalesce. More than 200 basic-science researchers and clinicians pool their knowledge and expertise with the shared objective of developing new knowledge to maintain health, prevent disease, and improve patient care. More than 900 people take part in advancing health sciences.
Centre hospitalier universitaire de Sherbrooke (CHUS) ::: www.chus.qc.ca
The Centre hospitalier universitaire de Sherbrooke has two constituent institutions: the CHUS - Fleurimont Hospital and the CHUS - Hôtel-Dieu. Its mission is fourfold: care, teaching, research, and assessment of health-care technologies and modes of intervention. The fourth largest hospital center in Quebec, the CHUS plays a triple role of local, regional, and supraregional hospital. The CHUS stands out for its many cutting-edge specialties such as gamma-knife radiosurgery, positron emission tomography (PET), interventional angiography, and neuro-oncology. The CHUS hospital community comprises nearly 10,000 individuals (employees, physicians, researchers, students, trainees, and volunteers) with a single objective: serving life.
My new avrg pps is $0.000125
trader. My AFPW average pps now is $0.000125
My AFPW average pps is now $0.000125
SPOM dd reposted.
'holla A lot of $$ on a triple 000 AFPW.
Just a little ahead on APDN after it dropped
on dilution and a bad 10-Q
May keep it ...
Hi 'holla.
Hi 'holla.
I don't have PM any longer.
At my new home on my profile.
Mike.
Sophiris Bio Inc. Files Registration Statement for Proposed Initial U.S. Public Offering on the NASDAQ
http://finance.yahoo.com/news/sophiris-bio-inc-files-registration-222400544.html
FDA bio Feb Mar.
03/31/2013 Johnson & Johnson JNJ Canagliflozin (NDA) (Trade name INVOKANA) FDA decision on INVOKANA for treatment of type 2 diabetes in adult patients
-Drug Status
03/31/2013 United Therapeutics Corp UTHR Oral Treprostinil (NDA resubmission) FDA decision on oral Treprostinil for treatment of pulmonary arterial hypertension.
03/27/2013 AP Pharma Inc APPA.OB APF530 (NDA resubmission) FDA decision on APF530 for prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting.
03/27/2013 Ariad Pharmaceuticals Inc ARIA Ponatinib (NDA) FDA decision on Ponatinib for patients with resistant or intolerant chronic myeloid leukemia or Philadelphia-chromosome positive acute lymphoblastic leukemia
03/17/2013 Bristol-Myers Squibb Co. BMY Eliquis (NDA resubmission) FDA decision on Eliquis to reduce risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation FDA approved Eliquis on Dec.28, 2012
-News
03/07/2013 GlaxoSmithKline PLC GSK, GSK.L BREO ELLIPTA (NDA) FDA panel to review BREO ELLIPTA for long-term maintenance treatment of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary disease.
03/04/2013 DEPOMED INC DEPO Serada (NDA) FDA panel to review Serada for the treatment of menopausal hot flashes
03/01/2013 Zogenix, Inc. ZGNX Zohydro ER (NDA) FDA decision on Zohydro ER for treating moderate to severe chronic pain
-News
02/26/2013 Immunogen Inc IMGN Trastuzumab emtansine (BLA) FDA decision on Trastuzumab emtansine for breast cancer
-News
02/24/2013 Dynavax Technologies Corp DVAX Heplisav (BLA) FDA decision on Heplisav for immunization against infection caused by all known subtypes of hepatitis B virus in adults 18 through 70 years of age
Health & Medicine News
http://www.sciencedaily.com/news/health_medicine/
Barchart Pinks.
http://www.barchart.com/stocks/pinkpa.php
Medical & Health News.
http://www.sciencedaily.com/news/top_news/top_health/
Fantastic Diva!!!
Crown Royal Hot Tottie;
Tasty and toasty - it’s the perfect drink for the holidays, and it’s sure to get you in the right spirit from the very first sip.
Ingredients:
Crown Royal® - 1.5 oz.
Heated Cider - 2 oz.
Honey - .25 oz.
Lemon Juice - .25 oz.
Serve in a warm coffee mug and sprinkle with cinnamon. Garnish with a cinnamon stick
Bio CEO & Investor Conference 2/12/13
Great companies and links to them.
http://www.bio.org/events/conferences/bio-ceo-2013-presenting-companies
I'd love to try all peaberry coffees.
Especially in Hawaii again.
5 Best Peaberry Kona Coffees
http://www.konacoffeebuzz.com/5-best-peaberry-kona-coffees
5 Best Peaberry Kona Coffees
http://www.konacoffeebuzz.com/5-best-peaberry-kona-coffees
My lotto pick, AFPW. avg'd $0.000133
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84398154
My lotto pick, AFPW. avg'd $0.000133
ALUMIFUEL POWER AND ITALIAN POWER SOLUTIONS COMPANY, GENPORT,
ANNOUNCE MERGER PLANS
http://www.alumifuelpowertech.com/?page_id=936
WSJournal. Are Polar Bears Really Disappearing?
Some say they're on the edge of extinction—but locals see a very different reality on the ground
A polar bear in Svalbard, Norway. There are 19 polar bear subpopulations world-wide. Roughly one-third are in decline, another third are steady or increasing and the others haven't been studied sufficiently.
I knew I was in trouble when the biologist from the Manitoba Conservation Department sat down next to me. "The bears look good," he said. "I haven't seen them this fat in years." We'd both been hanging around the tiny town of Churchill, Manitoba, ground zero for everything having to do with polar bears. Every fall the town is overrun with bears waiting for Hudson Bay to freeze. The bears, in turn, are trailed by herds of tourists, tour guides, scientists, green-leaning types and B-list celebrities—all looking for communion with The Most Important Animal of Our Time.
What worried me wasn't what the biologist had to say, but what the woman who had occupied that same seat three minutes earlier had said about the very same bears. A publicist for an environmental advocacy group, she shook her head ruefully. "It's just so sad," she exhaled. "They all look so skinny that it's hard to look at them."
I went north for a simple reason: I wanted to be a hero of the environmental movement and write a poetic obituary for a doomed species. The Center for Biological Diversity—the environmental group that sued the U.S. government to put polar bears on the Endangered Species list—had predicted that "two-thirds of the world's polar bears could be extinct by 2050."
But after months of reporting and hundreds of bear sightings, I kept running up against an inconvenient truth: There were a lot of well-meaning, well-credentialed scientists, wildlife officers and local experts who simply didn't believe that polar bears were one ice cube away from extinction. And they had the numbers to prove it.
Which was good news for the bears…even if it was terrible news for their careers as symbols of environmental doom.
Let's start with what we know. Almost everybody agrees that there are between 20,000 and 25,000 polar bears alive today. Here's another thing almost everyone agrees on: That number is a whole lot bigger than it was 40 years ago.
"Polar bears are one of the biggest conservation success stories in the world," says Drikus Gissing, wildlife director for the Canadian territory of Nunavut. "There are more bears here now than there were in the recent past." And since as many as half of the world's polar bears live in Nunavut, that's not an insignificant statement.
Exactly how much the bear population has grown in recent decades is a subject of intense debate. Some poorly sourced reports placed the earlier number as low as 5,000 animals world-wide, and in 1965, top scientists reported that extinction was in sight. By 1990, the consensus was that the threat had passed, and one expert declared the population could be as high as 40,000. Today, the pendulum has swung back to a gloomy forecast for the future.
The task is complicated by the fact that there isn't one monolithic polar bear population. There are 19 polar bear subpopulations world-wide. Between 1997 and 2004, the bear population of Baffin Bay fell by about one-quarter. Yet in Davis Strait, just to the south, the population has more than doubled since the 1970s.
And in Churchill, where tourists crowd into rumbling "Tundra Buggies" to watch polar bears cavort, the population fell from 1,194 to 935 between 1984 and 2004. After that 2004 count, scientists predicted that the population would crater to 676 bears by 2011. But a recent survey found more than 1,000 bears there, leading some government scientists to enthusiastically endorse increased hunting quotas.
Different factors account for the health of each population. In one area, a ban on the hunting of whitecoat harp seals led to an explosion in the bears' food supply. On the other end of the spectrum, one group of bears appears to be suffering because it has been hunted by indigenous people in both Canada and Greenland. Of the 19 subpopulations, some scientists argue that about one-third are decreasing and one-third are steady or increasing. The rest haven't been studied enough for anyone to know.
It's also important to remember that when people talk about decreases in sea ice, they're usually referring to summer sea ice. Nobody is predicting the disappearance of winter sea ice. Polar bears in the southern latitudes have been accustomed to ice-free summers since well before the Industrial Revolution. During these lean months, they don't go into caves but rather experience a "walking hibernation," eating very little and conserving their energy. If northerly bears start to have somewhat longer summers—as southern bears already do—the future might not be as catastrophic as some fear.
Despite the many real bits of heartening news, bad omens abound. Declines in polar-bear body condition have been widely observed. Recently it has become far less common to see adult females bearing twins or triplets. As Lily Peacock, a bear researcher with the U.S. Geological Survey, puts it, "Some populations appear to be doing OK now, but what's frightening is what might happen in the very near future."
Still, there are reasons to be upbeat. For one, the idea that polar bears can survive only on seal meat has been called into question; diet analysis shows that polar bears routinely eat caribou, vegetation and waterfowl. Indeed, the population of snow geese in the north has recently grown dramatically, and one study suggests that the abundance of goose nests could offset some of the nutrients lost because of a shorter seal-hunting season.
Mitch Taylor, who published almost 50 peer-reviewed papers during his 21 years as a polar-bear biologist and wildlife manager for the territorial government of Nunavut, prefers to avoid speculating too much about the unknown. "We don't know what the future holds, but we do know that many current populations are stable. And we have to manage for what we've got right now, not what we might have in the future."
Management decisions must be driven by scientific data, of course. Yet the experience of people who know bears best can't be entirely discounted. I found that people who actually live in polar-bear country say, by a wide margin, that they're seeing more bears than ever before.
One night as Churchill's "bear season" was gearing up, I sat down with Kevin Burke, a man who has lived with polar bears all his life, as both a Churchill native and a ranger in the deep bush country. He has also spent countless hours assisting the Ph.D.'s who study bears and predict their imminent demise. "I'm just starting to resent being told that I'm not seeing what I know abso-flipping-lutely damn well that I'm seeing with my own eyes," he said (using considerably more colorful language). With polar bears, it's not always black and white.
—Mr. Unger is the author of "Never Look a Polar Bear in the Eye," published this week by Da Capo.
A version of this article appeared February 9, 2013, on page C3 in the U.S. edition of The Wall Street Journal, with the headline: Are Polar Bears Really Disappearing?.
Diva. Have a great weekend.
Bio Updates reposted.
Bio Updates StocksDiva
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84350706
Eli Lilly and Company (NYSE: LLY) announced it will discontinue the Phase 3 rheumatoid arthritis (RA) program for tabalumab, an anti-BAFF (B cell activating factor) monoclonal antibody, due to lack of efficacy. The decision was not based on safety concerns. The tabalumab Phase 3 program for systemic lupus erythematosus, ILLUMINATE, is ongoing and will continue as planned.
In December 2012, Lilly discontinued the Phase 3 RA registration study FLEX-M for lack of treatment effect. FLEX-M was investigating tabalumab in patients with moderate-to-severe RA who had an inadequate response to methotrexate therapy.
Based on FLEX-M findings, an interim futility analysis was conducted of the FLEX-V study, which was investigating tabalumab for the treatment of patients with moderate-to-severe RA who had an inadequate response to one or more tumor necrosis factor (TNF) inhibitors.
Based on the outcomes of these two separate interim futility analyses, Lilly has decided to discontinue development of tabalumab in the current RA program. All ongoing Phase 2 and Phase 3 RA studies will be stopped.
"While we are obviously disappointed by these results in rheumatoid arthritis, we continue to believe that tabalumab could have significant potential for patients in other disease areas," said Eiry Roberts, M.D., vice president of autoimmune product development at Lilly. "Autoimmune disorders are highly individualized. We believe that targeting BAFF with a molecule such as tabalumab may still represent an important advance for patients, and therefore we will continue the ongoing Phase 3 tabalumab lupus program."
The decision to stop the current RA program for tabalumab is expected to result in a first-quarter charge to research and development expense of approximately $50 million. The company's previously issued financial guidance for 2013 remains unchanged.
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced it has successfully completed the first of a two-stage pharmacokinetic study with AVP-786, a drug product containing a deuterium modified form of dextromethorphan. Based on interim data, Avanir believes that it has identified a formulation of AVP-786 with a comparable pharmacokinetic, safety and tolerability profile to AVP-923 (dextromethorphan hydrobromide and quinidine sulfate). The company has requested a meeting with the FDA to discuss the full development path for AVP-786.
"The results of this study are very encouraging," said Joao Siffert, MD, chief scientific officer for Avanir. "We were able to successfully replicate the steady-state plasma levels of AVP-923, but with a substantially lower dose of quinidine. Given these results, we believe that AVP-786 would be an ideal candidate to test in one or more of our ongoing clinical programs."
Avanir also announced today that the company intends to modify the enrollment target of its ongoing phase II clinical study of AVP-923 in central neuropathic pain in multiple sclerosis to 200 patients.
"With the encouraging pharmacokinetic results in hand, we have made the decision to accelerate the completion of the PRIME study, as we believe AVP-786 has the potential to be a preferable development compound," said Joao Siffert, MD. "We plan to use the data from the PRIME study to guide the further development of AVP-786."
As a result of this change, the company now expects to have data from the PRIME study in the fourth calendar quarter of 2013.
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced it will present at the 15th Annual BIO CEO & Investor Conference on February 11th at 9:30am EST in the Basildon room at the Waldorf=Astoria in New York City.
Allergan, Inc. (NYSE: AGN) (“Allergan”) and MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) (“MAP”) today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to the tender offer for all of the outstanding shares of common stock of MAP by Groundhog Acquisition, Inc. (“Purchaser”), a wholly-owned subsidiary of Allergan.
Amgen (NASDAQ: AMGN) today outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City.
Anthera Pharmaceuticals, Inc.(Nasdaq: ANTH) a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced Paul F. Truex, Anthera's President and Chief Executive Officer, will present at the 2013 Leerink Global Healthcare Conference in New York, NY on Thursday, February 14, 2013 at approximately 8:00 am Eastern Time.
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Leerink Swann Global Healthcare Conference on Thursday, February 14, 2013 at 1:30 p.m.
CEL-SCI Corporation (NYSE MKT: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2013 BIO CEO & Investor Conference on Monday, February 11, 2013 at 11:00 a.m.
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), the first and largest cord blood banking operator in China, today announced the completion of the previously announced transaction with Cordlife Services (S) Pte. Ltd., a subsidiary of the Company's strategic affiliate, Cordlife Limited (CBB.AU) ("Cordlife"), a cord blood and tissue banking services provider listed on the Australian Securities Exchange.
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces the receipt of notice on February 1, 2013 from the NYSE MKT LLC (the “NYSE MKT”) that the NYSE MKT granted it an extension until April 15, 2013 to regain compliance with the continued listing standards of the NYSE MKT.
Digirad Corporation (NASDAQ: DRAD) announced today R. King Nelson, former Chairman, and Gerhard F. Burbach have tendered their resignations from the Board of Directors after more than a decade of service to the Board and management team at Digirad.
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced results from its randomized ReCharge Pivotal Trial of VBLOC® vagal blocking therapy for the treatment of obesity.
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, has appointed Mohan Gopalkrishnan as Vice President - Operations.
GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's fourth quarter and full year 2012 financial results on Thursday, February 21, at 9:00 a.m. Eastern Time.
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the three and twelve months ended December 31, 2012, following the close of the market on Tuesday, February 19, 2013.
Ingen Technologies, Inc. (PINKSHEETS: IGNT), an emerging medical device manufacturer with patented proprietary medical technology for the growing $55 Billion US home healthcare industry, is pleased to announce that Charles Vorwaller, a consultant with Ingen, has introduced Thomas Childers to the company and has agreed to help create sales of the Smart Nasal Cannula and Oxyview oxygen flow meter to his government clientele.
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, announced plans to release its financial results for the fourth quarter and full year 2012 on February 27, 2013 after the close of the financial markets.
KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) today announced the completion of its initial public offering of 8,750,000 shares of common stock at $8.00 per share.
LiveWire Ergogenics, Inc. (OTCQB: LVVV) has provided a corporate update of the company's activities and accomplishments in 2012 during which LiveWire completed the transition from a private company to a fully reporting public company with audited financials.
MeadWestvaco Corporation (NYSE: MWV), a global leader in packaging and packaging solutions, announced today the expansion of its pharmaceutical manufacturing Centre of Excellence, based in Hemer, Germany.
MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the fourth quarter ended December 31, 2012, will be released before the opening of the market on Thursday, March 7, 2013.
Novadaq® Technologies Inc. (TSX:NDQ) (NASDAQ:NVDQ), a developer of clinically-relevant fluorescence imaging solutions for use in surgical procedures, today announced financial results for its fourth quarter and full year ended December 31, 2012.
Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin associated serine protease-2 (MASP-2) program.
Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced that it will report financial results for the fourth quarter and full year 2012 ended December 31, 2012 after market closes on Thursday, February 21, 2013.
Opexa Therapeutics, Inc. (NASDAQ:OPXA) a company developing Tcelna™ (imilecleucel-T), a novel T-cell therapy for multiple sclerosis (MS), today announced it has priced an offering of shares of its common stock and warrants to purchase common stock in a private registered offering of 1,083,334 units at a price of $3.00 per unit, for gross proceeds of $3,250,000.
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced it will report fourth quarter and fiscal year 2012 financial results after the NASDAQ Global Market closes on February 28.
Oramed Pharmaceuticals Inc. (OTCQB: ORMPD), a developer of oral drug delivery systems, announced today that NASDAQ has approved the company's application to list its shares of common stock on the NASDAQ Capital Market.
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences.
Parametric Sound Corporation (NASDAQ: PAMT), a leading innovator of audio technology and solutions, today announced financial results for its first fiscal quarter ended December 31, 2012.
Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 15th Annual BIO CEO & Investor Conference.
RTI Biologics Inc. (RTI) (Nasdaq:RTIX), a leading provider of orthopedic and other biologic implants, reported operating results for the fourth quarter and full year of 2012.
SurePure, Inc. (OTCBB: SURP) a global leader in liquid photopurification, announced that Sigma Alimentos, a major Mexican food producer, would purchase at least three of its SurePure ultraviolet (UVC) photopurification systems.
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced it has signed its first European commercial development agreement with Netherlands-based EMELCA Bioscience for the initial phase of Venaxis' EU launch.
YM BioSciences Inc. (NYSE MKT: YMI) (TSX: YM), today reported operational and financial results for the second quarter of fiscal 2013, ended December 31, 2012.
Hi Diva.
Health & Medicine News
http://www.sciencedaily.com/news/health_medicine/
February 6, 2013 - 7:00 AM EST
AlumiFuel Power and Italian Power Solutions Company, Genport, Announce Merger Plans
http://media.marketwire.com/attachments/201209/85954_alumifuel.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=982330&ProfileId=051205&sourceType=1
PHILADELPHIA, PA -- (Marketwire) -- 02/06/13 -- Early production stage hydrogen generation company AlumiFuel Power Corporation (OTCBB: AFPW) (the "Company"), announced today that it has signed a Term Sheet with Genport, srl of Italy, which would merge its wholly-owned Philadelphia-based operating subsidiary, AlumiFuel Power Technologies, Inc., (APTI) and Genport into a new U.S. corporate entity, NovoFuel, Inc. This initiative is the result of continuing Joint Venture discussions between the parties, as reported in the AFPW news release of November 28, 2012. This term sheet will be the basis for, and the parties are moving forward toward completion of, a definitive agreement through which both parties would own 50% of NovoFuel before any future financings.
The merger would combine and integrate the synergistic technologies, Intellectual Property, products, revenues, engineering staffs, manufacturing operations, marketing, sales and services activities of both companies, including a new lab facility in the Philadelphia area. The focus of NovoFuel would be to pursue and capture backup and portable power applications and business opportunities in the U.S., Europe, and other market areas -- multi-billion dollar markets. The new entity would pursue the engineering development of an integrated 5kW backup power system for telecom facilities.
NovoFuel would encompass the following capabilities of both companies: (1) APTI's AlumiFuel powder and cartridge-based hydrogen generation for fuel cell power, weather balloon lift gas and Unmanned Undersea Vehicle power; and (2) Genport/GNA's fuel cell power systems, hydrogen generation and storage systems, solar cells and lithium-ion battery packs. Genport's current flagship product is the G300 Hybrid Fuel Cell, a European certified 400 Watt system that can take energy inputs from hydrogen, solar panels and lithium-ion battery packs and deliver electricity for a variety of applications including military, emergency telecommunications, PCs, battery charging, electro-medical devices, and auxiliary power.
The next steps in the merger process include executing the definitive Merger Agreement, completing the capital raising effort already underway by Colebrooke Capital Ventures of New York City, and converting NovoFuel into a public entity at the appropriate time.
AlumiFuel Power Technologies' President & CEO, Mr. David Cade, said: "NovoFuel would be a true alternative energy company with global reach, and we are excited about introducing customers around the world to the advanced energy capabilities of this new company."
Genport's Chief Executive Officer, Mr. Paolo Fracas, said: "NovoFuel will offer significant new power solutions for portable electronics, backup power, and micro-grid users. The introduction of our new multi-technology, extended run-time fuel cells for various critical mission applications will offer tremendous new market opportunities for us."
Completion of this transaction is subject to, among other things, further due diligence by the parties, negotiation and execution of definitive agreements, and any board of director and/or stockholder approvals that may be necessary.
About AlumiFuel Power Corporation (www.alumifuelpowercorp.com)
AlumiFuel Power Corporation, operating through its wholly owned subsidiary, AlumiFuel Power Technologies, Inc., is an early production stage alternative energy company that generates hydrogen gas and steam/heat through the chemical reaction of aluminum powder, water, and proprietary additives. This technology is ideally suited for multiple applications requiring on-site, on-demand fuel sources, serving National Security and commercial customers. The Company's hydrogen feeds fuel cells for portable and back-up power; fills inflatable devices such as weather balloons; can replace costly, hard-to-handle and high pressure K-Cylinders; and provides fuel for flameless heater applications. Its hydrogen/heat output is also being designed and developed to drive fuel cell-based and turbine-based undersea propulsion systems and auxiliary power systems. The Company has significant differentiators in performance, adaptability, safety and cost-effectiveness in its target market applications, with no external power required and no toxic chemicals or by-products
About Genport,srl (www.genport.it)
Genport srl is an advanced power solutions company based near Milan, Italy. Genport is focused on providing clean, safe, reliable and high performance portable power sources for medical, defense, emergency, telecommunications, and industrial applications. Genport's solutions are designed to store and generate electrical energy anytime, anywhere. Genport combines solid hydrogen PEM fuel cell, lithium ion battery and solar cell technologies to: provide a constant, reliable source of power; maximize power and energy density; eliminate noise, emissions and operate in extreme environmental conditions. Genport/GNA's technology partners include Milan Polytechnic, Texas Instruments, Arbin Instruments, four European companies, and Purdue University.
Safe Harbor for Forward-looking Statements
This news release may contain forward-looking statements that are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, they are based on management's current beliefs and assumptions as to future events. However, since the company's operations and business prospects are always subject to risk and uncertainties, the forward-looking events and circumstances discussed in this news release might not occur, and actual results could differ materially from those described, anticipated or implied. For a more complete discussion of such risks and uncertainties, please refer to the company's filings with the Securities and Exchange Commission.
February 6, 2013 - 7:00 AM EST
AlumiFuel Power and Italian Power Solutions Company, Genport, Announce Merger Plans
http://media.marketwire.com/attachments/201209/85954_alumifuel.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=982330&ProfileId=051205&sourceType=1
PHILADELPHIA, PA -- (Marketwire) -- 02/06/13 -- Early production stage hydrogen generation company AlumiFuel Power Corporation (OTCBB: AFPW) (the "Company"), announced today that it has signed a Term Sheet with Genport, srl of Italy, which would merge its wholly-owned Philadelphia-based operating subsidiary, AlumiFuel Power Technologies, Inc., (APTI) and Genport into a new U.S. corporate entity, NovoFuel, Inc. This initiative is the result of continuing Joint Venture discussions between the parties, as reported in the AFPW news release of November 28, 2012. This term sheet will be the basis for, and the parties are moving forward toward completion of, a definitive agreement through which both parties would own 50% of NovoFuel before any future financings.
The merger would combine and integrate the synergistic technologies, Intellectual Property, products, revenues, engineering staffs, manufacturing operations, marketing, sales and services activities of both companies, including a new lab facility in the Philadelphia area. The focus of NovoFuel would be to pursue and capture backup and portable power applications and business opportunities in the U.S., Europe, and other market areas -- multi-billion dollar markets. The new entity would pursue the engineering development of an integrated 5kW backup power system for telecom facilities.
NovoFuel would encompass the following capabilities of both companies: (1) APTI's AlumiFuel powder and cartridge-based hydrogen generation for fuel cell power, weather balloon lift gas and Unmanned Undersea Vehicle power; and (2) Genport/GNA's fuel cell power systems, hydrogen generation and storage systems, solar cells and lithium-ion battery packs. Genport's current flagship product is the G300 Hybrid Fuel Cell, a European certified 400 Watt system that can take energy inputs from hydrogen, solar panels and lithium-ion battery packs and deliver electricity for a variety of applications including military, emergency telecommunications, PCs, battery charging, electro-medical devices, and auxiliary power.
The next steps in the merger process include executing the definitive Merger Agreement, completing the capital raising effort already underway by Colebrooke Capital Ventures of New York City, and converting NovoFuel into a public entity at the appropriate time.
AlumiFuel Power Technologies' President & CEO, Mr. David Cade, said: "NovoFuel would be a true alternative energy company with global reach, and we are excited about introducing customers around the world to the advanced energy capabilities of this new company."
Genport's Chief Executive Officer, Mr. Paolo Fracas, said: "NovoFuel will offer significant new power solutions for portable electronics, backup power, and micro-grid users. The introduction of our new multi-technology, extended run-time fuel cells for various critical mission applications will offer tremendous new market opportunities for us."
Completion of this transaction is subject to, among other things, further due diligence by the parties, negotiation and execution of definitive agreements, and any board of director and/or stockholder approvals that may be necessary.
About AlumiFuel Power Corporation (www.alumifuelpowercorp.com)
AlumiFuel Power Corporation, operating through its wholly owned subsidiary, AlumiFuel Power Technologies, Inc., is an early production stage alternative energy company that generates hydrogen gas and steam/heat through the chemical reaction of aluminum powder, water, and proprietary additives. This technology is ideally suited for multiple applications requiring on-site, on-demand fuel sources, serving National Security and commercial customers. The Company's hydrogen feeds fuel cells for portable and back-up power; fills inflatable devices such as weather balloons; can replace costly, hard-to-handle and high pressure K-Cylinders; and provides fuel for flameless heater applications. Its hydrogen/heat output is also being designed and developed to drive fuel cell-based and turbine-based undersea propulsion systems and auxiliary power systems. The Company has significant differentiators in performance, adaptability, safety and cost-effectiveness in its target market applications, with no external power required and no toxic chemicals or by-products
About Genport,srl (www.genport.it)
Genport srl is an advanced power solutions company based near Milan, Italy. Genport is focused on providing clean, safe, reliable and high performance portable power sources for medical, defense, emergency, telecommunications, and industrial applications. Genport's solutions are designed to store and generate electrical energy anytime, anywhere. Genport combines solid hydrogen PEM fuel cell, lithium ion battery and solar cell technologies to: provide a constant, reliable source of power; maximize power and energy density; eliminate noise, emissions and operate in extreme environmental conditions. Genport/GNA's technology partners include Milan Polytechnic, Texas Instruments, Arbin Instruments, four European companies, and Purdue University.
Safe Harbor for Forward-looking Statements
This news release may contain forward-looking statements that are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, they are based on management's current beliefs and assumptions as to future events. However, since the company's operations and business prospects are always subject to risk and uncertainties, the forward-looking events and circumstances discussed in this news release might not occur, and actual results could differ materially from those described, anticipated or implied. For a more complete discussion of such risks and uncertainties, please refer to the company's filings with the Securities and Exchange Commission.
CONTACTS:
AlumiFuel Power Investor Relations:
AlumiFuel Power Corporation
Thomas B. Olson
Corporate Secretary
303-796-8940
Technical Information & Marketing:
Email Contact
610-660-7775
Genport srl
Via Lecco, 61
20871 Vimercate (MB) - Italy
Email Contact
+39 039 639 6500
Genport North America Corp.
1281 Win Hentschel Blvd.
West Lafayette, IN 47906
Email Contact
765-237-3393
Source: Marketwire (February 6, 2013 - 7:00 AM EST)
Not selling my AFPW at $0.0002
The Hook. I am not selling my AFPW at $0.0002
From ScreenRant. Full commercials.
http://screenrant.com/super-bowl-commercials-2013/